398 related articles for article (PubMed ID: 11016631)
21. Suppression of pulmonary CYP2A13 expression by carcinogen-induced lung tumorigenesis in a CYP2A13-humanized mouse model.
Liu Z; Megaraj V; Li L; Sell S; Hu J; Ding X
Drug Metab Dispos; 2015 May; 43(5):698-702. PubMed ID: 25710941
[TBL] [Abstract][Full Text] [Related]
22. Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes.
Wong HL; Zhang X; Zhang QY; Gu J; Ding X; Hecht SS; Murphy SE
Chem Res Toxicol; 2005 Jun; 18(6):913-8. PubMed ID: 15962925
[TBL] [Abstract][Full Text] [Related]
23. Characterization of cytochrome P450 2A4 and 2A5-catalyzed 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism.
Felicia ND; Rekha GK; Murphy SE
Arch Biochem Biophys; 2000 Dec; 384(2):418-24. PubMed ID: 11368333
[TBL] [Abstract][Full Text] [Related]
24. Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model.
Wei Y; Wu H; Li L; Liu Z; Zhou X; Zhang QY; Weng Y; D'Agostino J; Ling G; Zhang X; Kluetzman K; Yao Y; Ding X
Drug Metab Dispos; 2012 Jun; 40(6):1144-50. PubMed ID: 22397853
[TBL] [Abstract][Full Text] [Related]
25. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
Carcinogenesis; 2000 Jun; 21(6):1227-32. PubMed ID: 10837014
[TBL] [Abstract][Full Text] [Related]
26. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody.
Zhu LR; Thomas PE; Lu G; Reuhl KR; Yang GY; Wang LD; Wang SL; Yang CS; He XY; Hong JY
Drug Metab Dispos; 2006 Oct; 34(10):1672-6. PubMed ID: 16815959
[TBL] [Abstract][Full Text] [Related]
27. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.
DeVore NM; Scott EE
J Biol Chem; 2012 Aug; 287(32):26576-85. PubMed ID: 22700965
[TBL] [Abstract][Full Text] [Related]
28. A high-level expression of CYP2A in the lung of the suncus (Suncus murinus) and its role in the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Mushiroda T; Ariyoshi N; Kimura K; Takahara E; Nagata O; Kato H; Kamataki T
Biochem Biophys Res Commun; 2000 Mar; 269(2):393-6. PubMed ID: 10708563
[TBL] [Abstract][Full Text] [Related]
29. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
[TBL] [Abstract][Full Text] [Related]
30. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes.
DeVore NM; Smith BD; Wang JL; Lushington GH; Scott EE
Drug Metab Dispos; 2009 Jun; 37(6):1319-27. PubMed ID: 19251817
[TBL] [Abstract][Full Text] [Related]
31. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant.
Wang SL; He XY; Shen J; Wang JS; Hong JY
Toxicol Sci; 2006 Nov; 94(1):38-45. PubMed ID: 16917071
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.
Miyazaki M; Yamazaki H; Takeuchi H; Saoo K; Yokohira M; Masumura K; Nohmi T; Funae Y; Imaida K; Kamataki T
Carcinogenesis; 2005 Nov; 26(11):1947-55. PubMed ID: 15958517
[TBL] [Abstract][Full Text] [Related]
33. CYP2A6 polymorphisms and risk for tobacco-related cancers.
Rossini A; de Almeida Simão T; Albano RM; Pinto LF
Pharmacogenomics; 2008 Nov; 9(11):1737-52. PubMed ID: 19018727
[TBL] [Abstract][Full Text] [Related]
34. Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.
von Weymarn LB; Brown KM; Murphy SE
J Pharmacol Exp Ther; 2006 Jan; 316(1):295-303. PubMed ID: 16188955
[TBL] [Abstract][Full Text] [Related]
35. Expression of CYP2A genes in rodent and human nasal mucosa.
Su T; Sheng JJ; Lipinskas TW; Ding X
Drug Metab Dispos; 1996 Aug; 24(8):884-90. PubMed ID: 8869824
[TBL] [Abstract][Full Text] [Related]
36. Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.
D'Agostino J; Zhang X; Wu H; Ling G; Wang S; Zhang QY; Liu F; Ding X
Drug Metab Dispos; 2008 Nov; 36(11):2316-23. PubMed ID: 18669584
[TBL] [Abstract][Full Text] [Related]
37. Expression and alternative splicing of the cytochrome P-450 CYP2A7.
Ding S; Lake BG; Friedberg T; Wolf CR
Biochem J; 1995 Feb; 306 ( Pt 1)(Pt 1):161-6. PubMed ID: 7864805
[TBL] [Abstract][Full Text] [Related]
38. Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa.
Chen Y; Liu YQ; Su T; Ren X; Shi L; Liu D; Gu J; Zhang QY; Ding X
Biochem Pharmacol; 2003 Oct; 66(7):1245-51. PubMed ID: 14505803
[TBL] [Abstract][Full Text] [Related]
39. 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor.
Hecht SS; Hochalter JB; Villalta PW; Murphy SE
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12493-7. PubMed ID: 11050152
[TBL] [Abstract][Full Text] [Related]
40. Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK.
Xu Y; Shen Z; Shen J; Liu G; Li W; Tang Y
J Mol Graph Model; 2011 Sep; 30():1-9. PubMed ID: 21680215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
